期刊文献+

老年男性骨密度与骨代谢指标分析 被引量:3

Analysis of bone mineral density and bone metabolic biochemical markers in 220 elderly men
原文传递
导出
摘要 目的观察老年男性骨密度与骨代谢特点。方法人选220例老年男性住院患者,根据年龄分为三组,测量骨密度及甲状旁腺激素(PTH)、骨钙素(BGP)、25-羟维生素D(25-OHVD)等骨代谢指标。结果老年男性随着年龄增长,骨质疏松患病率增高,65~74岁组、75~84岁组及85~94岁组的骨质疏松患病率分别为6.8%、12.0%与22.9%(x2=7.72,P〈0.05)。老年男性骨代谢特点是,PTH随年龄增长呈上升趋势(F=4.986,P〈0.05),BGP、25-OHVD随年龄增长呈下降趋势(F=4.986,3.245,5.997,P〈0.05),老年人中BGP、25-OHVD水平普遍较低。结论老年男性骨质疏松患病率高,骨代谢可以作为骨质疏松风险评估的辅助指标,有助于原发性骨质疏松的早期诊断。 Objective To study the characteristics of bone mineral density and bone metabolism in elderly men. Methods 220 male elderly hospitalized patients were selected and divided into three groups according to age: 65-74 years group, 75-84 years group and 85-94 years group. Bone mineral density and bone metabolic biochemical makers including serum parathyroid hormone (PTH), bone gla-protein (BGP) and 25-dihydroxy vitamin D (25-OH VD) were detected. Results The prevalence of osteoporosis was increased along with ageing in three groups (6.8%, 12.0% vs. 22.9%, respectively, F=4. 986,P〈0.05). The characteristics of bone metabolism showed that serum PTH level was increased and serum levels of BGP, 25-OH VD were decreased along with ageing (F= 4. 986,3. 245,5. 997,all P〈0.05), and the levels of BGP, 25-OH VD were generally decreased in elderly men. Conclusions The prevalence of osteoporosis is high in elderly men. Bone metabolism can be used as the auxiliary index for osteoporosis risk assessment, which is helpful for the early diagnosis of primary osteoporosis.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2013年第11期1183-1185,共3页 Chinese Journal of Geriatrics
基金 北京市保健科研课题(京11-02)
关键词 骨质疏松 骨密度 骨代谢 Osteoporosis Bone mineral density Bone metabolism
  • 相关文献

参考文献7

二级参考文献22

  • 1Burge R, Dawson-Hughes B, Solomon DH, et al. incidence and e- conomic burden of osteoporosis-related fractures in the United States ,2005-2025 [ J]. J Bone Miner Res ,2007,22:465 - 475.
  • 2Brown JP,Fortier M,Frame H, et al. Canadian Consensus Confer- ence on osteoporosis, 2006 update. Osteoporosis Guidelines Com- mittee[ J]. J Obstet Gynaecol Can, 2006,28 ( 2 Suppl 1 ) : S95 - 112.
  • 3Riggs BL,Melton LJ, Robb RA,et al. A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites [ J ]. J Bone Miner Res, 2004,19 (12) :1945 - 1954.
  • 4Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis[ J]. Endocrinol Metab Clin N Am, 2005,34 (4): 1015 - 1030.
  • 5Sun L, Peng YZ, Sharrow AC, et at. FSH directly regulates bone mass[ J]. Cell ,2006,125 ( 2 ) :247 - 260.
  • 6Cummings SR, San Martin J, McClung MR, et al, for the FREE- DOM Trial. Denosumab for prevention of fractures in postmenopa- usal women with osteoporosis [ J]. N Engl J Med ,2009,361:756 - 765.
  • 7Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density [ J ]. J Bone Miner Res, 2010,25 : 937 - 947.
  • 8Hannon RA,Clack G,Rimmer M,et al. Eft ects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending- dose phase I trial[ J ]. J Bone Miner Res ,2010,25:463 -471.
  • 9Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD:a random- ized, placebo-controlled, dose-ranging study in postmenopausal wmnen with low BMD [ J ]. Bone,2009,45 ( 5 ) :833 - 842.
  • 10Widler L. Caleilytics:antagonists of the calcium-sensing receptor for the treatment of osteoporosis [ J ]. Future Med Chem, 2011,3 (5) :535-547.

共引文献176

同被引文献18

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部